Latest Insider Transactions at Regeneron Pharmaceuticals, Inc. (REGN)
This section provides a real-time view of insider transactions for Regeneron Pharmaceuticals, Inc. (REGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of REGENERON PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of REGENERON PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 22
2022
|
Daniel P Van Plew EVP & General Mgr Industrial O |
SELL
Payment of exercise price or tax liability
|
Direct |
33,219
-47.07%
|
$20,263,590
$610.56 P/Share
|
|
Feb 22
2022
|
Daniel P Van Plew EVP & General Mgr Industrial O |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+36.17%
|
$15,960,000
$399.66 P/Share
|
|
Feb 18
2022
|
Neil Stahl EVP Research and Development |
SELL
Bona fide gift
|
Direct |
335
-0.63%
|
-
|
|
Feb 15
2022
|
Andrew J Murphy EVP Research |
SELL
Open market or private sale
|
Direct |
3,540
-0.53%
|
$2,226,660
$629.34 P/Share
|
|
Feb 14
2022
|
Andrew J Murphy EVP Research |
SELL
Payment of exercise price or tax liability
|
Direct |
6,460
-9.43%
|
$4,043,960
$626.79 P/Share
|
|
Feb 14
2022
|
Andrew J Murphy EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.74%
|
$1,790,000
$179.13 P/Share
|
|
Feb 01
2022
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
1,000
-4.84%
|
$607,000
$607.46 P/Share
|
|
Feb 01
2022
|
Marion Mc Court EVP Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+4.62%
|
$342,000
$342.93 P/Share
|
|
Feb 01
2022
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.04%
|
$60,600
$606.04 P/Share
|
|
Jan 04
2022
|
P Roy Vagelos Director |
SELL
Bona fide gift
|
Indirect |
338
-0.24%
|
-
|
|
Jan 03
2022
|
Michael S Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
191
+15.0%
|
-
|
|
Jan 03
2022
|
Joseph L Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
191
+3.04%
|
-
|
|
Jan 03
2022
|
George L Sing Director |
BUY
Grant, award, or other acquisition
|
Direct |
191
+0.63%
|
-
|
|
Jan 03
2022
|
Arthur F Ryan Director |
BUY
Grant, award, or other acquisition
|
Direct |
191
+0.84%
|
-
|
|
Jan 03
2022
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.06%
|
$62,500
$625.07 P/Share
|
|
Jan 03
2022
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
191
+15.0%
|
-
|
|
Jan 03
2022
|
N Anthony Coles Director |
BUY
Grant, award, or other acquisition
|
Direct |
191
+14.88%
|
-
|
|
Jan 03
2022
|
Marc Tessier Lavigne Director |
BUY
Grant, award, or other acquisition
|
Direct |
191
+7.76%
|
-
|
|
Jan 03
2022
|
Huda Y Zoghbi Director |
BUY
Grant, award, or other acquisition
|
Direct |
191
+15.0%
|
-
|
|
Jan 03
2022
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
1,000
-4.84%
|
$625,000
$625.0 P/Share
|
|
Jan 03
2022
|
Marion Mc Court EVP Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+4.62%
|
$342,000
$342.93 P/Share
|
|
Jan 03
2022
|
Christine A Poon Director |
BUY
Grant, award, or other acquisition
|
Direct |
191
+9.26%
|
-
|
|
Dec 22
2021
|
George Yancopoulos President and Chief Scientific |
SELL
Payment of exercise price or tax liability
|
Direct |
310,097
-13.52%
|
$189,159,170
$610.04 P/Share
|
|
Dec 22
2021
|
George Yancopoulos President and Chief Scientific |
BUY
Exercise of conversion of derivative security
|
Direct |
442,267
+16.15%
|
$99,067,808
$224.78 P/Share
|
|
Dec 16
2021
|
P Roy Vagelos Director |
SELL
Discretionary transaction
|
Indirect |
126
-2.86%
|
$79,884
$634.87 P/Share
|
|
Dec 13
2021
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
344
-1.72%
|
$224,632
$653.12 P/Share
|
|
Dec 13
2021
|
Robert E Landry EVP Finance CFO |
SELL
Open market or private sale
|
Direct |
116
-0.39%
|
$76,792
$662.5 P/Share
|
|
Dec 11
2021
|
Daniel P Van Plew EVP & General Mgr Industrial O |
SELL
Payment of exercise price or tax liability
|
Direct |
697
-2.23%
|
$462,808
$664.34 P/Share
|
|
Dec 11
2021
|
Marion Mc Court EVP Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
388
-1.9%
|
$257,632
$664.34 P/Share
|
|
Dec 11
2021
|
Joseph J Larosa EVP General Counsel and Secret |
SELL
Payment of exercise price or tax liability
|
Direct |
697
-2.61%
|
$462,808
$664.34 P/Share
|
|
Dec 11
2021
|
Neil Stahl EVP Research and Development |
SELL
Payment of exercise price or tax liability
|
Direct |
753
-1.4%
|
$499,992
$664.34 P/Share
|
|
Dec 11
2021
|
Andrew J Murphy EVP Research |
SELL
Payment of exercise price or tax liability
|
Direct |
697
-1.18%
|
$462,808
$664.34 P/Share
|
|
Dec 11
2021
|
Christopher R. Fenimore VP Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
270
-1.26%
|
$179,280
$664.34 P/Share
|
|
Dec 11
2021
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
697
-2.32%
|
$462,808
$664.34 P/Share
|
|
Dec 10
2021
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,384
-4.4%
|
$918,976
$664.34 P/Share
|
|
Dec 10
2021
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+4.55%
|
$832,500
$555.67 P/Share
|
|
Dec 10
2021
|
Robert E Landry EVP Finance CFO |
SELL
Open market or private sale
|
Direct |
781
-0.16%
|
$518,584
$664.66 P/Share
|
|
Dec 10
2021
|
Andrew J Murphy EVP Research |
SELL
Open market or private sale
|
Direct |
7,122
-0.71%
|
$4,729,008
$664.97 P/Share
|
|
Dec 09
2021
|
Marc Tessier Lavigne Director |
SELL
Open market or private sale
|
Direct |
3,784
-64.55%
|
$2,516,360
$665.0 P/Share
|
|
Dec 09
2021
|
Marc Tessier Lavigne Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,784
+39.23%
|
$1,403,864
$371.4 P/Share
|
|
Dec 09
2021
|
Joseph J Larosa EVP General Counsel and Secret |
SELL
Payment of exercise price or tax liability
|
Direct |
19,772
-42.5%
|
$12,990,204
$657.11 P/Share
|
|
Dec 09
2021
|
Joseph J Larosa EVP General Counsel and Secret |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+39.21%
|
$5,370,000
$179.13 P/Share
|
|
Dec 09
2021
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,469
-10.14%
|
$2,279,133
$657.11 P/Share
|
|
Dec 09
2021
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,250
+11.05%
|
$1,695,750
$399.66 P/Share
|
|
Dec 09
2021
|
Andrew J Murphy EVP Research |
SELL
Payment of exercise price or tax liability
|
Direct |
9,378
-12.39%
|
$6,161,346
$657.11 P/Share
|
|
Dec 09
2021
|
Andrew J Murphy EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
16,500
+17.9%
|
$858,000
$52.03 P/Share
|
|
Dec 08
2021
|
Christopher R. Fenimore VP Controller |
BUY
Grant, award, or other acquisition
|
Direct |
1,859
+8.0%
|
-
|
|
Dec 08
2021
|
Joseph J Larosa EVP General Counsel and Secret |
BUY
Grant, award, or other acquisition
|
Direct |
3,338
+16.81%
|
-
|
|
Dec 08
2021
|
Marion Mc Court EVP Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
3,338
+14.08%
|
-
|
|
Dec 08
2021
|
Neil Stahl EVP Research and Development |
BUY
Grant, award, or other acquisition
|
Direct |
2,926
+5.15%
|
-
|